Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2000

View Archived Issues

NeoRx's STR product continues to show positive phase I/II results

Ciblex's CBX-21404 shows biological activity in mice

LU-135252 and trandolapril studied in type 1 diabetes model for effects on angiopathy

Panacea and Case Western to collaborate on AD models

Virosome influenza vaccine comparable to subunit vaccine in pediatric CF

Agouron's HRV 3C protease inhibitor shows positive in vitro results

Adenosine A2A receptor agonists compare favorably to PDGF in mouse wound model

Antiinflammatory effects of new A2A agonist DWH-146e described at Purines 2000

Antidepressant EMD-68843 alters sleep in humans

Naturally produced antiangiogenic agent identified by Eisai and Mercian

Colesevelam heads for first market launch

Novel nucleoside transport inhibitor NU-3108 deemed suitable for further development

NK1 antagonists alter behavior in rodent models of antidepressant activity

CVT-2759 as an alternative to adenosine A1 receptor full agonists

FDA approves Malarone for prevention and treatment of malaria

Sch-58261, an adenosine A2A antagonist, exerts beneficial effects in rat models of HD and PD

CPMP recommends approval of Ligand's Panretin Gel

Potent benzomaltoside-based inhibitors of smooth muscle cell proliferation

FDA clears ConjuChem to initiate phase I/II trial of thrombin inhibitor

Sankyo claims potent tachykinin antagonist series

Nicotinic acetylcholine receptor ligands under study at major French laboratory

N. meningitidis polypeptides and their use patented by SB

Potential new antimigraine agents with an indole structure reported by Lilly

SB researchers synthesize potent new vitronectin receptor antagonist

New antiemetics from Takeda prove effective in range of animal models

BMS to conduct new study of omapatrilat as treatment for hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.